Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,181.3
1.9 (0.06%)

 

  • STI Straits Times Index
    3,181.3
    1.9 (0.06%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,602.9
    4.6 (0.29%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,713.3
    -187.5 (-0.65%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,390.1
    -26.6 (-0.78%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,681.0
    60.0 (0.20%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,061.2
    10.9 (0.18%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 383.7M
  • Value: 298.4M
  • Rise: 116
  • Fall: 97
  • Unch: 557

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
CWX Global0.004-0.001
Sembcorp Marine0.200+0.003
P5 Capital0.039+0.001
Jiutian Chemical0.099-0.002
Adventus0.017+0.001
Rex Intl0.183-
Oceanus^0.041-0.001
MM2 Asia0.058-0.001
Genting Sing0.900-0.005
Anchor Resources0.031-

World Indices

World Indices
Name Last Change
Nasdaq 13,857.8 -138.3
HSI 28,665.4 -235.5
HSCEI 10,863.4 -135.9
Jakarta 6,039.5 -10.8
Nikkei 225 29,660.2 +39.2
SSE Comp 3,380.3 -36.5
Shanghai A 3,543.0 -38.2
Shanghai B 245.3 -0.7
KOSPI 3,191.4 +9.0

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

JOINN JOINN
Quotes 15 Minutes Delayed. Updated at 15 Apr 2021 10:35
Last (HKD): 131.500 Change: -1.400 High: 135.000 Remarks: -
Change (%): -1.05 Low: 130.800
Open 132.900 Yesterday's Close 132.900
Buy Price 131.500 Sell Price 132.300
Buy Volume ('000) 0.8 Sell Volume ('000) 0.3
Cumulative Volume ('000) 34.3 Cumulative Value 4,534,990
Click to show Stock Prices chart

Key Statistics

EPS (HKD) a 1.30706 Trailing EPS (HKD) e 1.30706 NAV (HKD) b 5.3626
PE a 100.607 Trailing PE f 100.607 Price / NAV b 24.5217
Dividend (HKD) d 0.329223 Cash In Hand (HKD) g 1.3514 Issued & Paid-up Shares c 43,365,600
Dividend Yield (%) d 0.250 Price / Cash In Hand g 97.306 Treasury Shares h -
Beta - 75 Daysi 1.036 R-Squared - 75 Days(%)i 21.49 Market Cap (M) 35,612.909
Beta - 500 Daysi 1.027 R-Squared - 500 Days (%)i 21.63 Enterprise Value (M) 35,003.542
Piotroski F Score 7 Exchange Code 6127 Par Value ( CNY ) 1.00000
52 Weeks Volatility (%) n.a. 6-Month VWAP n.a. Free Float (%) 99.9
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 24 Mar 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 19 Feb 2021.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference JOINN HKEx 35,612.909 100.607 100.607 24.5217 0.250
Industry Biotechnology HKEx 48,725.905 - - 7.8822 0.015
Local Peer WUXI BIO HKEx 437,643.337 230.605 230.607 17.9494 -
Local Peer BEIGENE HKEx 214,104.752 - - 7.1365 -
Local Peer SINO BIOPHARM HKEx 151,075.079 48.517 48.517 7.6085 -
Local Peer ZAI LAB-SB HKEx 112,230.855 - - 12.3781 -
Local Peer GENSCRIPT BIO HKEx 29,578.663 - - 4.2305 -
Local Peer 3SBIO HKEx 17,601.712 18.742 18.742 1.3888 -
Local Peer VIVA BIOTECH HKEx 13,297.464 - - 2.9854 0.388
Local Peer JACOBIO-B HKEx 12,821.698 - - 6.0542 -
Local Peer JW THERAP-B HKEx 12,298.385 - - 3.0244 -
Local Peer KINTOR PHARMA-B HKEx 12,332.162 - - 6.8977 -
Local Peer HAOHAI BIOTEC HKEx 10,910.971 42.204 42.204 1.6760 -
Local Peer ALPHAMAB-B HKEx 10,265.630 - - 3.8091 -
Other Local Peers FRONTAGE (HKEx), ASCENTAGE-B (HKEx), JHBP-B (HKEx), SINOMAB BIO-B (HKEx), LEE'S PHARM (HKEx), ESSEX BIO-TECH (HKEx), ASCLETIS-B (HKEx), REGENT PACIFIC (HKEx)
Global Peer AMGEN INC NASDAQ 143,731.695 19.787 19.787 15.2760 2.575
Global Peer CSL LTD ASX 121,881.136 38.861 32.025 11.5338 1.096
Global Peer GILEAD SCIENCES INC NASDAQ 82,055.980 667.143 667.122 4.5081 4.157
Global Peer MODERNA INC NASDAQ 64,040.805 - - 25.0023 -
Global Peer ILLUMINA INC NASDAQ 58,078.413 88.534 88.534 12.3729 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 56,197.804 20.725 20.725 6.4693 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 51,547.619 14.673 14.673 4.6754 -
Global Peer BIOGEN INC NASDAQ 40,016.013 10.003 10.003 3.7397 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 34,306.822 56.856 56.856 2.9445 -
Global Peer BIONTECH SE SPON ADS EACH REP 1 ORD SHS NASDAQ 32,025.685 1,848.599 1,848.489 19.0797 -
Other Global Peers BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), SEAGEN INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), BIO-TECHNE CORP (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), FATE THERAPEUTICS (NASDAQ), EXELIXIS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), OLINK HLDG AB SPON ADS EACH REP 1 ORD SHS (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), Lonza (SGX), ALLOGENE THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), VERACYTE INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), SEER INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), INSMED INC (NASDAQ), ALKERMES PLC (NASDAQ), ARVINAS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ORGANOGENESIS HOLDINGS INC (NASDAQ), INSTIL BIO INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), NUVATION BIO INC (NYSE), ARCUS BIOSCIENCES INC (NYSE), MYRIAD GENETICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), BIONANO GENOMICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), FIBROGEN INC (NASDAQ), MACROGENICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), BIOATLA INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), ALLOVIR INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), IMMUNOVANT INC (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), POLYNOVO LIMITED (ASX), REGENXBIO INC (NASDAQ), PRECIGEN INC (NASDAQ), IMMUNOGEN INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ALECTOR INC (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), MIMEDX GROUP INC (NASDAQ), EDGEWISE THERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), TRANSLATE BIO INC (NASDAQ), OCUGEN INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), NKARTA INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), AFFIMED N V (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), MESOBLAST LTD (ASX), OMEROS CORP (NASDAQ), VOR BIOPHARMA INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CURIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), PERSONALIS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), VAXCYTE INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), VANDA PHARMACE INC (NASDAQ), HUMANIGEN INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), TELIX PHARMACEUTIC (ASX), MERUS B V (NASDAQ), PASSAGE BIO INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), INHIBRX INC (NASDAQ), EPIZYME INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), COMPUGEN (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), CHIMERIX INC (NASDAQ), IMMATICS N V (NASDAQ), ARDELYX INC (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), VAXART INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), ATHIRA PHARMA INC (NASDAQ), KADMON HLDGS INC (NASDAQ), IMUGENE LIMITED (ASX), RIGEL PHARMACEUTICALS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), MEIRAGTX HOLDINGS PLC (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), IKENA ONCOLOGY INC (NASDAQ), AGENUS INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), IVERIC BIO INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), DPHARMA (Bursa), AKOUOS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), ALTIMMUNE INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), VERASTEM INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), GERON CORP (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), ATRECA INC (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), XOMA CORP (NASDAQ), ANTEOTECH LIMITED (ASX), CHEMOMAB THERAPEUTICS LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), OPTHEA LIMITED (ASX), HOMOLOGY MEDICINES INC (NASDAQ), LAVA THERAPEUTICS NV (NASDAQ), ADICET BIO INC (NASDAQ), SESEN BIO INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), SPRUCE BIOSCIENCES INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ATHERSYS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), SQZ BIOTECHNOLOGIES CO (NYSE), ONCORUS INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PORTAGE BIOTECH INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), IMMUNOME INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), EIGER BIOPHARMACEUTICALS INC (NASDAQ), TREVENA INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), KAMADA LTD (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), NEXTCURE INC (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), IMMUTEP LTD (ASX), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), MEDICINOVA INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), NEXT SCIENCE LTD (ASX), MEDICENNA THERAPEUTICS CORP (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), SAVARA INC (NASDAQ), BIOVIE INC (NASDAQ), EQUILLIUM INC (NASDAQ), IMV INC (NASDAQ), EVOGENE LTD (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), AXCELLA HEALTH INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), INMUNE BIO INC (NASDAQ), CHIASMA INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), FENNEC PHARMACEUTICALS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), CONTRAFECT CORP (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), BIOMX INC (NYSE American), GAIN THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CEL-SCI CORP (NYSE American), BIONOMICS LTD (ASX), SIO GENE THERAPIES INC (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), LONGEVERON INC (NASDAQ), IBIO INC (NYSE American), AZIYO BIOLOGICS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SYNLOGIC INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ORGENESIS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), METACRINE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ARAVIVE INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), CIDARA THERAPEUTICS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), LEAP THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), RECRO PHARMA INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), MERRIMACK PHARMACEUTICALS INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), AVALON GLOBOCARE CORP (NASDAQ), LEAF RESOURCES LTD (ASX), AIKIDO PHARMA INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), ADVAXIS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), COHBAR INC (NASDAQ), CHIMERIC THERAPEUTICS LTD (ASX), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), VACCINEX INC (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), GENETIC TECHNOLOGIES (ASX), BIOCARDIA INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), SOLIGENIX INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), ARCA BIOPHARMA INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), IDERA PHARMACEUTICALS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), MEMPHASYS LTD (ASX), ADITX THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), PATRYS LIMITED (ASX), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), HISTOGEN INC (NASDAQ), ORAGENICS INC (NYSE American), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), GEOVAX LABS INC (NASDAQ), PRECIPIO INC (NASDAQ), Suntar Eco-City (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), PHIO PHARMACEUTICALS CORP (NASDAQ), BIOTRON (ASX), ADALTA LTD (ASX), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), REGENEUS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BELLICUM PHARMACEUTICALS (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), INMED PHARMACEUTICALS INC (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), BENITEC BIOPHARMA INC (NASDAQ), RHINOMED LIMITED (ASX), BRIACELL THERAPEUTICS CORP (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), CONSTELLATION TECHNOLOGIES LTD (ASX), SENESTECH INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), CRYOSITE (ASX), NANOLLOSE LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --6.300
-4.57 %
10 Days --2.900
-2.16 %
20 Days --7.500
-5.40 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 125.000 - 150.500 Change From 1 Year Low +6.500 % Change From 1 Year Low (%) +5.20
Change From 1 Year High -19.000 % Change From 1 Year High (%) -12.62
2 Years Range 125.000 - 150.500 Change From 2 Years Low +6.500 % Change From 2 Years Low (%) +5.20
Change From 2 Years High -19.000 % Change From 2 Years High (%) -12.62
5 Years Range 125.000 - 150.500 Change From 5 Years Low +6.500 % Change From 5 Years Low (%) +5.20
Change From 5 Years High -19.000 % Change From 5 Years High (%) -12.62
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

JOINN Laboratories (China) Co., Ltd. engages in the provision of drug pre-clinical research services, and the sale of laboratory animals. It provides non-clinical safety evaluation services for drugs, pharmacodynamics research services, animal pharmacokinetics research services, and drug screening. The company was founded by Yu Xia Feng on August 11, 1995 and is headquartered in Beijing, China.

Historical Price Data

Date Open High Low Close Volume VWAP
14 Apr 2021 137.000 137.000 132.800 132.900 149,228 133.9625
13 Apr 2021 137.600 138.700 135.000 135.000 98,900 136.1454
12 Apr 2021 139.600 140.000 135.000 137.600 101,400 137.2801
09 Apr 2021 142.500 142.500 139.600 140.300 54,700 140.1909
08 Apr 2021 137.800 144.200 137.000 142.500 184,000 141.8585
07 Apr 2021 139.000 141.000 137.100 137.800 161,010 139.0909
01 Apr 2021 134.700 139.400 134.700 139.000 177,700 137.3029
31 Mar 2021 138.000 138.000 134.000 134.400 110,300 135.6000
30 Mar 2021 140.100 140.800 136.300 137.000 189,631 138.2508
29 Mar 2021 135.200 141.200 135.200 138.200 204,400 139.6309
26 Mar 2021 131.000 140.400 131.000 137.400 181,500 137.4901
25 Mar 2021 131.900 136.000 125.000 131.000 164,900 132.2668
24 Mar 2021 134.000 134.700 130.200 132.100 140,200 131.9195
23 Mar 2021 137.600 138.300 133.900 133.900 206,713 135.0898
22 Mar 2021 146.600 146.600 137.300 137.600 191,220 140.6783
19 Mar 2021 144.200 150.500 143.000 150.500 1,262,150 146.7498
18 Mar 2021 139.000 144.000 138.400 144.000 1,727,804 140.3293
17 Mar 2021 134.800 139.000 131.700 139.000 814,100 134.4502
16 Mar 2021 131.500 133.400 131.500 133.000 316,020 132.4925
15 Mar 2021 133.600 133.700 130.700 131.500 365,500 132.5764
12 Mar 2021 137.100 137.800 130.000 131.500 590,100 132.7428
11 Mar 2021 130.000 135.000 130.000 134.000 211,000 133.7603
Summary
Current 2 Weeks
(29 Mar 2021 to 14 Apr 2021)
135.200 144.200 132.800 132.900 1,431,269 -
Previous 2 Weeks
(15 Mar 2021 to 26 Mar 2021)
133.600 144.200 130.700 137.400 5,370,107 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.